FI954351A0 - Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina - Google Patents

Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina

Info

Publication number
FI954351A0
FI954351A0 FI954351A FI954351A FI954351A0 FI 954351 A0 FI954351 A0 FI 954351A0 FI 954351 A FI954351 A FI 954351A FI 954351 A FI954351 A FI 954351A FI 954351 A0 FI954351 A0 FI 954351A0
Authority
FI
Finland
Prior art keywords
alkyl
group
phenyl
pct
hydrogen atom
Prior art date
Application number
FI954351A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI954351A (fi
Inventor
Michael John Grimmin
Paul Raymond Beckett
Mark Hampton Davis
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939305348A external-priority patent/GB9305348D0/en
Priority claimed from GB939320360A external-priority patent/GB9320360D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of FI954351A0 publication Critical patent/FI954351A0/fi
Publication of FI954351A publication Critical patent/FI954351A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI954351A 1993-03-16 1995-09-15 Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina FI954351A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939305348A GB9305348D0 (en) 1993-03-16 1993-03-16 Hydroxamic acid derivatives as metalloproteinase inhibitors
GB939320360A GB9320360D0 (en) 1993-10-02 1993-10-02 Hydroxamic acid derivatives as metalloproteinase inhibitors
PCT/GB1994/000495 WO1994021625A1 (en) 1993-03-16 1994-03-14 Hydroxamic acid derivatives as metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
FI954351A0 true FI954351A0 (fi) 1995-09-15
FI954351A FI954351A (fi) 1995-09-15

Family

ID=26302598

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954351A FI954351A (fi) 1993-03-16 1995-09-15 Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina

Country Status (12)

Country Link
US (1) US5652262A (de)
EP (1) EP0689538B1 (de)
JP (1) JPH08508027A (de)
AT (1) ATE169621T1 (de)
AU (1) AU671724B2 (de)
CA (1) CA2158352A1 (de)
DE (1) DE69412469T2 (de)
FI (1) FI954351A (de)
GB (1) GB2290543B (de)
NO (1) NO953652D0 (de)
NZ (1) NZ262447A (de)
WO (1) WO1994021625A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5872101A (en) * 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
GB9502858D0 (en) * 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
WO1996030381A1 (en) * 1995-03-28 1996-10-03 Novo Nordisk A/S Immunosuppressive agents
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
AU2986295A (en) * 1995-07-19 1997-02-18 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
HUP9903863A3 (en) 1995-11-23 2000-11-28 British Biotech Pharm Metalloproteinase inhibitors
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
ES2181021T3 (es) 1996-09-10 2003-02-16 British Biotech Pharm Derivados citostaticos del acido hidroxamico.
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
HUP0105412A2 (hu) * 1999-01-13 2002-05-29 Jomaa Pharmaka Gmbh. 3-Izoxazolidinon- és karboxi-alkil-hidroxámsav-származékok alkalmazása fertőzések kezelésére szolgáló gyógyszerkészítmények előállítására
GB9901863D0 (en) * 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
KR100799192B1 (ko) 2000-07-19 2008-01-31 미쯔비시 웰 파마 가부시키가이샤 히드록삼산계 설폰산 유도체 및 그의 의약 용도
BRPI0407587A (pt) * 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
WO2004101537A1 (en) * 2003-05-17 2004-11-25 British Biotech Pharmaceuticals Ltd Metalloproteinase inhibitors
WO2005014825A2 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005086915A2 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
WO1992009564A1 (en) * 1990-12-03 1992-06-11 Celltech Limited Peptidyl derivatives
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives

Also Published As

Publication number Publication date
AU671724B2 (en) 1996-09-05
DE69412469D1 (de) 1998-09-17
NO953652L (no) 1995-09-15
NO953652D0 (no) 1995-09-15
FI954351A (fi) 1995-09-15
CA2158352A1 (en) 1994-09-29
GB2290543A (en) 1996-01-03
JPH08508027A (ja) 1996-08-27
DE69412469T2 (de) 1999-02-04
US5652262A (en) 1997-07-29
WO1994021625A1 (en) 1994-09-29
ATE169621T1 (de) 1998-08-15
NZ262447A (en) 1996-07-26
GB9517704D0 (en) 1995-11-01
EP0689538B1 (de) 1998-08-12
EP0689538A1 (de) 1996-01-03
AU6213194A (en) 1994-10-11
GB2290543B (en) 1996-05-22

Similar Documents

Publication Publication Date Title
FI954351A0 (fi) Hydroksaamihappojohdannaiset metalloproteinaasi-inhibiittoreina
NO911962D0 (no) Hydroksaminsyrebaserte kollagenaseinhibitorer.
KR927003624A (ko) 화합물
GB9902452D0 (en) Chemical compounds
LU91140I2 (fr) Duloxètine et ses sels d'addition acides pharmaceutiquement acceptables et particulièrement chlorhydrate de duloxétine (ARICLAIM).
DK1252133T3 (da) Farmaceutiske forbindelser
ES2102195T3 (es) Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
DK1295871T3 (da) Vitamin D-derivater med et 22-oxa- eller 22-thiaatom, en C17-sidekæde substitueret med en syre-, ester- eller amid-gruppe og en 16(17)-dobbeltbinding
DE69723258T2 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
NO305165B1 (no) 1-Arylcykloalkylsulfider, -sulfoksyder og -sulfoner, farmas°ytiske preparater og anvendelse derav
ATE99934T1 (de) Heteroaryl-3-oxo-propannitril-derivate, nuetzlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
IL150965A0 (en) Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative
IL122247A0 (en) Use of sulfamic acid derivatives acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
AU2001228862A1 (en) Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives
MX9709275A (es) Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas.